Payment overview · 2025
General Payments
$217.88
11 reported records · 5 companies
Healthcare provider profile · identity verified
Ryan Andrew Hackett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELIZABETHTON, TN · NPI 1710140249
Verified facts
What the public records show
CMS Open Payments records show Ryan Andrew Hackett, M.D. received $217.88 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.21 | 34.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.70 | 29.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$47.73 | 21.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.68 | 8.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.56 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $217.88 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.19 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 148 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 108 |
| Omeprazole | Omeprazole | 426 | 115 |
| Lisinopril | Lisinopril | 419 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 334 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 89 |
| Furosemide | Furosemide | 282 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 73 |
| Losartan Potassium | Losartan Potassium | 258 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 242 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 63 |
| Gabapentin | Gabapentin | 212 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 202 | 49 |
| Trazodone Hcl | Trazodone Hcl | 199 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 52 |
| Metformin Hcl | Metformin Hcl | 177 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 48 |
| Simvastatin | Simvastatin | 163 | 46 |
| Promethazine Hcl | Promethazine Hcl | 161 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 46 |
| Eliquis | Apixaban | 148 | 34 |
| Meloxicam | Meloxicam | 139 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 37 |
| Glipizide | Glipizide | 131 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 35 |
| Alendronate Sodium | Alendronate Sodium | 124 | 33 |
| Potassium Chloride | Potassium Chloride | 121 | 33 |
| Allopurinol | Allopurinol | 118 | 31 |
| Ibuprofen | Ibuprofen | 111 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 35 |
| Prednisone | Prednisone | 105 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 23 |
| Pregabalin | Pregabalin | 95 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 26 |
| Buspirone Hcl | Buspirone Hcl | 92 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 30 |
| Ozempic | Semaglutide | 84 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 20 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Celecoxib | Celecoxib | 80 | 25 |
| Ondansetron Odt | Ondansetron | 79 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 25 |
| Carvedilol | Carvedilol | 75 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 19 |
| Xarelto | Rivaroxaban | 72 | 12 |
| Famotidine | Famotidine | 70 | 18 |
| Metformin Hcl Er | Metformin Hcl | 65 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | 15 |
| Chlorthalidone | Chlorthalidone | 61 | 17 |
| Atenolol | Atenolol | 56 | 14 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Spironolactone | Spironolactone | 46 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Nystatin | Nystatin | 44 | 16 |
| Lovastatin | Lovastatin | 43 | 12 |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Amoxicillin | Amoxicillin | 40 | 36 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | 11 |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Azithromycin | Azithromycin | 36 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 20 |
| Sertraline Hcl | Sertraline Hcl | 33 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Diazepam | Diazepam | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Fluconazole | Fluconazole | 31 | 18 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Finasteride | Finasteride | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 19 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $217.88 · 11 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, ELIQUIS, MINIMED 780G, Ozempic, Rybelsus, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error